FDA approves Izervay for geographic atrophy tied to age-related macular degeneration

The U.S. Food and Drug Administration has approved Izervay (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy secondary to age-related macular degeneration.

The approval was based on two phase 3 clinical trials, in which patients received 2 mg intravitreal administration of Izervay. During a 12-month follow-up period, there was a statistically significant…